4.4 Article

Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells

期刊

RNA
卷 22, 期 2, 页码 303-315

出版社

COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1261/rna.052571.115

关键词

feedback loop regulation; AXL; miR-34a; JNK; ELK1; apoptosis

资金

  1. National Health Research Institutes [CA-104-PP-14, CA-104-SP-01]
  2. Ministry of Health and Welfare [MOHW104-TDU-B-212-124-008]
  3. Ministry of Science and Technology, Taiwan [MOST-103-2320-B-400-009, NSC 99-2314-B-400-001-MY3]

向作者/读者索取更多资源

The AXL receptor tyrosine kinase is frequently overexpressed in cancers and is important in cancer invasion/metastasis and chemoresistance. Here, we demonstrate a regulatory feedback loop between AXL and microRNA (miRNA) at the post transcriptional level. Both the GAS6-binding domain and the kinase domain of AXL, particularly the Y779 tyrosine phosphorylation site, are shown to be crucial for this autoregulation. To clarify the role of miRNAs in this regulation loop, approaches using bioinformatics and molecular techniques were applied, revealing that miR-34a may target the 3' UTR of AXL mRNA to inhibit AXL expression. Interestingly and importantly, AXL overexpression may induce miR-34a expression by activating the transcription factor ELK1 via the JNK signaling pathway. In addition, ectopic overexpression of ELK1 promotes apoptosis through, in part, down-regulation of AXL. Therefore, we propose that AXL is autoregulated by miR-34a in a feedback loop; this may provide a novel opportunity for developing AXL-targeted anticancer therapies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Editorial Material Gastroenterology & Hepatology

Pursuing efficacious systemic therapy for hepatocellular carcinoma

Ann-Lii Cheng

Summary: In 2020, combination treatments have significantly improved the efficacy of systemic therapy for HCC, with different drug combinations showing high therapeutic effects, establishing new standards and directions for future treatment of HCC.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)

Article Oncology

Association between risk factors, molecular features and CpG island methylator phenotype colorectal cancer among different age groups in a Taiwanese cohort

Kuo-Hsing Chen, Liang-In Lin, Chang-Tsu Yuan, Li-Hui Tseng, Yu-Liang Chao, Yi-Hsin Liang, Jin-Tung Liang, Been-Ren Lin, Ann-Lii Cheng, Kun-Huei Yeh

Summary: In Taiwan, distinct clinicopathological features were identified for CIMP-high CRC among different age groups. Our data suggest the association between BMI >= 27.5 kg/m(2) and CIMP-high CRC in patients younger than 50 years.

BRITISH JOURNAL OF CANCER (2021)

Article Oncology

Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression

Baek-Yeol Ryoo, Ann-Li Cheng, Zhenggang Ren, Tae-You Kim, Hongming Pan, Kun-Ming Rau, Hye Jin Choi, Joong-Won Park, Jee Hyun Kim, Chia Jui Yen, Ho Yeong Lim, Dongli Zhou, Josef Straub, Juergen Scheele, Karin Berghoff, Shukui Qin

Summary: This study evaluated the efficacy of the MET inhibitor Tepotinib in Asian patients with aHCC, showing improved time to progression and better tolerability compared to sorafenib.

BRITISH JOURNAL OF CANCER (2021)

Article Cell Biology

YAP-Dependent BiP Induction Is Involved in Nicotine-Mediated Oral Cancer Malignancy

Chu-Yen Chien, Ying-Chen Chen, Chia-Chen Hsu, Yu-Ting Chou, Shine-Gwo Shiah, Shyun-Yeu Liu, Alexander Cheng-Ting Hsieh, Ching-Yu Yen, Chien-Hsing Lee, Yi-Shing Shieh

Summary: Nicotine induces the expression of BiP in oral squamous cell carcinoma cells through the activation of the YAP-TEAD transcriptional complex, leading to increased malignancy. Inhibition of BiP expression can suppress nicotine-induced malignant behaviors, including epithelial-mesenchymal transition, migration, and invasion.
Review Oncology

MicroRNAs: Their Role in Metabolism, Tumor Microenvironment, and Therapeutic Implications in Head and Neck Squamous Cell Carcinoma

Shine-Gwo Shiah, Sung-Tau Chou, Jang-Yang Chang

Summary: Head and neck squamous cell carcinoma (HNSCC) is a common cancer arising from the oral epithelium, with high mortality rates despite improvements in diagnosis and treatment. Dysregulation of exosomes and metabolic abnormalities are involved in the development of HNSCC, suggesting potential therapeutic targets. MiRNAs play important roles in regulating HNSCC progression and may serve as non-invasive biomarkers for diagnosis and treatment.

CANCERS (2021)

Review Oncology

Current Status of the Spectrum and Therapeutics of Helicobacter pylori-Negative Mucosa-Associated Lymphoid Tissue Lymphoma

Sung-Hsin Kuo, Kun-Huei Yeh, Chung-Wu Lin, Jyh-Ming Liou, Ming-Shiang Wu, Li-Tzong Chen, Ann-Lii Cheng

Summary: The prevalence of HP-negative gastric MALT lymphoma has increased, while HP-positive gastric MALT lymphoma has decreased. Some case studies have shown that a first-line HP eradication therapy (HPE)-like regimen can result in complete remission for some patients with localized HP-negative gastric MALT lymphoma. Previous sporadic reports have also indicated that some patients with extragastric MALT lymphoma can respond to antibiotic treatment.

CANCERS (2022)

Article Oncology

Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma

Yu-Yun Shao, Pai-Sheng Chen, Liang-In Lin, Bin-Shyun Lee, Andrew Ling, Ann-Lii Cheng, Chiun Hsu, Da-Liang Ou

Summary: This study identified miR-10b-3p as a potential biomarker for predicting sorafenib efficacy in advanced HCC patients and confirmed its mechanism of action.

BRITISH JOURNAL OF CANCER (2022)

Article Oncology

Transcriptional suppression of Dicer by HOXB-AS3/EZH2 complex dictates sorafenib resistance and cancer stemness

Chi-Feng Tseng, Li-Tzong Chen, Horng-Dar Wang, Yi-Hong Liu, Shine-Gwo Shiah

Summary: The HOXB-AS3/EZH2 complex plays a significant role in causing sorafenib resistance and enhancing cancer stemness by epigenetically suppressing Dicer expression in liver cancer. These findings provide potential therapeutic strategies for diagnosing and treating liver cancer patients.

CANCER SCIENCE (2022)

Article Oncology

Novel prognostic implications of complement activation in the tumour microenvironment for de novo metastatic BRAF V600E mutant colorectal cancer

Kuo-Hsing Chen, Chia-Lang Hsu, Yu-Li Su, Chang-Tsu Yuan, Liang-In Lin, Jia-Huei Tsai, Yi-Hsin Liang, Ann-Lii Cheng, Kun-Huei Yeh

Summary: This study found that the immune contexture in the tumor microenvironment is closely associated with prognosis in patients with metastatic BRAF V600E mutant colorectal cancer. High expression of immune genes and complement activation are correlated with poor prognosis, and the complement score is strongly correlated with tumor-associated macrophage M2 signatures.

BRITISH JOURNAL OF CANCER (2023)

Article Gastroenterology & Hepatology

Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study

Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang-Hyub Han, Kenji Ikeda, Ann-Lii Cheng, Arndt Vogel, Francesco Tovoli, Kazuomi Ueshima, Hiroshi Aikata, Carlos Lopez Lopez, Marc Pracht, Zhiqiang Meng, Bruno Daniele, Joong-Won Park, Daniel Palmer, Toshiyuki Tamai, Kenichi Saito, Corina E. Dutcus, Riccardo Lencioni

Summary: The study aimed to validate objective response as an independent predictor of overall survival (OS) in individuals with unresectable hepatocellular carcinoma (HCC) receiving systemic anti-angiogenic therapy. The results showed that objective response assessed by investigator-assessed mRECIST could predict the survival of patients. Further studies are needed to confirm this finding.

JOURNAL OF HEPATOLOGY (2023)

Article Oncology

Cyclin Dependent Kinase 9 Inhibition as a Potential Treatment for Hepatocellular Carcinoma

Yu-Yun Shao, Hung-Wei Hsu, Rita Robin Wo, Han-Yu Wang, Ann-Lii Cheng, Chih-Hung Hsu

Summary: CDK9 inhibitors have been found to have potent anti-proliferative and apoptosis-inducing activities against HCC cells, while inhibiting downstream signaling molecules' phosphorylation. Animal experiments have confirmed the inhibitory effects of CDK9 inhibitors on HCC. Overexpression of CDK9 reduced the efficacy of CDK9 inhibitors, while knockdown of CDK9 expression reduced the proliferative activities of HCC cells.

ONCOLOGY (2022)

Article Gastroenterology & Hepatology

Topoisomerase I Inhibition Radiosensitizing Hepatocellular Carcinoma by RNF144A-mediated DNA-PKcs Ubiquitination and Natural Killer Cell Cytotoxicity

Chiao-Ling Tsai, Po-Sheng Yang, Feng-Ming Hsu, Ann-Lii Cheng, Wan-Ni Yu, Jason Chia-Hsien Cheng

Summary: This study investigated the effect of TOP1 inhibition and DNA-PKcs/RNF144A mechanism on radiosensitization mediated by natural killer (NK) cells in radiation therapy (RT). The results showed that TOP1 inhibitors and RT had a synergistic effect on hepatocellular carcinoma (HCC) cells, enhancing the anti-HCC effect of RT through increased DNA damage and DNA-PKcs signaling. RNF144A mediated DNA-PKcs ubiquitination and provided a reason for the difference in radiosensitization effect between HCC cells.

JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY (2023)

Article Oncology

Selective inhibition of HDAC6 promotes bladder cancer radiosensitization and mitigates the radiation-induced CXCL1 signalling

Yu-Chieh Tsai, Tzu-Yin Wang, Chia-Lang Hsu, Wei-Chou Lin, Jyun-Yu Chen, Jia-Hua Li, Yeong-Shiau Pu, Ann-Lii Cheng, Jason Chia-Hsien Cheng, Sheng-Fang Su

Summary: This study found that inhibiting HDAC6 can enhance the radiosensitivity of bladder cancer and reduce the expression of genes related to cell migration, angiogenesis, and metastasis induced by radiotherapy, thereby improving therapeutic efficacy.

BRITISH JOURNAL OF CANCER (2023)

Article Oncology

Albumin-Bilirubin Grade Analyses of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study

Masatoshi Kudo, Richard S. Finn, Ann-Lii Cheng, Andrew X. Zhu, Michel Ducreux, Peter R. Galle, Naoya Sakamoto, Naoya Kato, Michitaka Nakano, Jing Jia, Arndt Vogel

Summary: This exploratory analysis examined the prognostic impact of baseline albumin-bilirubin (ALBI) score in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab + bevacizumab or sorafenib. The study found that atezolizumab + bevacizumab improved overall survival and progression-free survival compared to sorafenib in patients with ALBI score of 1, but not in patients with ALBI score of 2. ALBI grade appeared to be prognostic for outcomes in both treatment groups.

LIVER CANCER (2023)

Article Oncology

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer-Term Follow-Up From the Phase 3 KEYNOTE-240 Trial

Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Ann-Lii Cheng, Stephen Lam Chan, Thomas Yau, Marcelo Garrido, Jennifer Knox, Bruno Daniele, Valeriy Breder, Ho Yeong Lim, Sadahisa Ogasawara, Stephane Cattan, Yee Chao, Abby B. Siegel, Ivan Martinez-Forero, Ziwen Wei, Chih-Chin Liu, Richard S. Finn

Summary: With extended follow-up, pembrolizumab demonstrated continued improvement in overall survival (OS) and progression-free survival (PFS) compared to placebo in advanced hepatocellular carcinoma (HCC) patients previously treated with sorafenib. The adverse event profile of pembrolizumab remained consistent with placebo.

LIVER CANCER (2023)

暂无数据